Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Recruiting3
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

not_yet_recruiting120%
unknown120%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_1

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

NCT06217757
not_yet_recruitingphase_3

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

NCT05700448
recruitingphase_3

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

NCT06617416
recruitingphase_2

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

NCT05623267
unknown

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

NCT05131438

Clinical Trials (5)

Showing 5 of 5 trials
NCT06217757Phase 1

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Recruiting
NCT05700448Phase 3

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not Yet Recruiting
NCT06617416Phase 3

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting
NCT05623267Phase 2

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Recruiting
NCT05131438

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5